GKOS:NYE-Glaukos Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 130.28

Change

+1.99 (+1.55)%

Market Cap

USD 1.10B

Volume

0.36M

Analyst Target

USD 48.89
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+1.58 (+1.41%)

USD 198.37B
MDT Medtronic PLC

+0.71 (+0.79%)

USD 115.25B
STE STERIS plc

+3.49 (+1.46%)

USD 23.57B
ZBH Zimmer Biomet Holdings Inc

-0.27 (-0.25%)

USD 22.04B
SNN Smith & Nephew SNATS Inc

+0.02 (+0.06%)

USD 13.37B
GMED Globus Medical

+0.93 (+1.32%)

USD 9.55B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.22B
BIO Bio-Rad Laboratories Inc

+2.81 (+0.85%)

USD 9.22B
PEN Penumbra Inc

+2.76 (+1.44%)

USD 7.80B
INSP Inspire Medical Systems Inc

+8.57 (+4.23%)

USD 6.35B

ETFs Containing GKOS

AWEG The Alger ETF Trust 6.28 % 0.00 %

+0.13 (+0.00%)

USD 4.69M
PSCH Invesco S&P SmallCap Heal.. 4.60 % 0.29 %

+0.53 (+0.00%)

USD 0.20B
XSMO Invesco S&P SmallCap Mome.. 2.10 % 0.39 %

+0.33 (+0.00%)

USD 0.99B
IJT iShares S&P Small-Cap 600.. 1.05 % 0.25 %

+0.56 (+0.00%)

USD 6.49B
VIOG Vanguard S&P Small-Cap 60.. 0.98 % 0.20 %

+0.23 (+0.00%)

USD 0.98B
MWON:XETRA Amundi S&P SmallCap 600 E.. 0.79 % 0.00 %

-0.37 (0.00%)

USD 0.14B
USASUS:SW Amundi S&P SmallCap 600 E.. 0.79 % 0.00 %

N/A

USD 0.14B
CBUSAS:SW Amundi S&P SmallCap 600 E.. 0.75 % 0.00 %

N/A

N/A
ESIX SPDR S&P SmallCap 600 ESG.. 0.74 % 0.00 %

+0.14 (+0.00%)

USD 6.30M
SPSM SPDR® Portfolio S&P 600 .. 0.52 % 0.06 %

+0.18 (+0.00%)

USD 11.77B
ISP6:LSE iShares III Public Limite.. 0.52 % 0.00 %

-38.50 (0.00%)

USD 2.02B
BBSC JPMorgan BetaBuilders U.S.. 0.45 % 0.00 %

+0.16 (+0.00%)

USD 0.53B
SAA ProShares Ultra SmallCap6.. 0.37 % 0.95 %

+0.25 (+0.00%)

USD 0.04B
SLYG SPDR® S&P 600 Small Cap .. 0.00 % 0.15 %

+0.23 (+0.00%)

N/A
VIOO Vanguard S&P Small-Cap 60.. 0.00 % 0.15 %

+0.35 (+0.00%)

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-2.45 (0.00%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 63.89% 92% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.89% 92% A 97% N/A
Trailing 12 Months  
Capital Gain 83.23% 89% A- 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 83.23% 89% A- 95% A
Trailing 5 Years  
Capital Gain 124.08% 85% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 124.08% 85% B 86% B+
Average Annual (5 Year Horizon)  
Capital Gain 29.59% N/A N/A 89% A-
Dividend Return 29.59% N/A N/A 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.86% N/A N/A 17% F
Risk Adjusted Return 55.98% N/A N/A 72% C
Market Capitalization 1.10B 67% D+ 81% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 42.30 36% 6%
Price/Book Ratio 10.60 9% 9%
Price / Cash Flow Ratio -122.05 98% 98%
Price/Free Cash Flow Ratio -57.89 98% 98%
Management Effectiveness  
Return on Equity -27.49% 23% 13%
Return on Invested Capital -16.66% 26% 10%
Return on Assets -7.96% 40% 10%
Debt to Equity Ratio 61.24% 34% 53%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector